Nektar Therapeutics Finalizes Upsized $373.75M Public Offering at Near-Market Price to Fund Phase 3 Trials

summarizeSummary

Nektar Therapeutics completed an upsized public offering, raising $350.9 million in net proceeds at near-market pricing, including the full exercise of the over-allotment option, to fund its ongoing clinical development, particularly Phase 3 trials for rezpegaldesleukin.

check_boxKey Events

• Upsized Public Offering Finalized

  Nektar Therapeutics completed an underwritten public offering, selling a total of 4,062,500 shares of common stock.

• Significant Capital Raised

  The offering generated approximately $350.9 million in net proceeds for the company.

• Underwriters Fully Exercise Option

  The underwriters fully exercised their 30-day option to purchase an additional 529,891 shares, demonstrating strong demand.

• Favorable Pricing

  Shares were priced at $92.00, a minimal discount to the current market price, reflecting investor confidence following recent positive clinical data.

auto_awesomeAnalysis

Nektar Therapeutics has finalized an upsized public offering, raising approximately $350.9 million in net proceeds by selling a total of 4,062,500 shares at $92.00 per share. This includes the full exercise of the underwriters' over-allotment option for an additional 529,891 shares. The offering was priced at a minimal discount to the current market price, indicating strong investor confidence. This substantial capital raise, representing about 13.5% of the company's market capitalization, is strategically timed following recent positive Phase 2b clinical trial results for rezpegaldesleukin. The proceeds are earmarked for general corporate purposes, including critical research and development, clinical development (specifically Phase 3 trials for rezpegaldesleukin), and manufacturing costs, significantly extending the company's financial runway for its key drug candidates.